false Q3 0000718937 --01-01 P3Y P1Y4M24D P10M24D P8Y10M24D P5Y2M12D P5Y4M17D P5Y8M19D P5Y4M17D P5Y8M19D 0000718937 2021-01-02 2021-10-01 xbrli:shares 0000718937 2021-10-29 iso4217:USD 0000718937 2021-10-01 0000718937 2021-01-01 iso4217:USD xbrli:shares 0000718937 2021-07-03 2021-10-01 0000718937 2020-07-04 2020-10-02 0000718937 2020-01-04 2020-10-02 0000718937 us-gaap:CommonStockMember 2021-07-02 0000718937 us-gaap:AdditionalPaidInCapitalMember 2021-07-02 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-02 0000718937 us-gaap:RetainedEarningsMember 2021-07-02 0000718937 2021-07-02 0000718937 us-gaap:RetainedEarningsMember 2021-07-03 2021-10-01 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-03 2021-10-01 0000718937 us-gaap:CommonStockMember 2021-07-03 2021-10-01 0000718937 us-gaap:AdditionalPaidInCapitalMember 2021-07-03 2021-10-01 0000718937 us-gaap:CommonStockMember 2021-10-01 0000718937 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 0000718937 us-gaap:RetainedEarningsMember 2021-10-01 0000718937 us-gaap:CommonStockMember 2020-07-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-07-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-03 0000718937 us-gaap:RetainedEarningsMember 2020-07-03 0000718937 2020-07-03 0000718937 us-gaap:RetainedEarningsMember 2020-07-04 2020-10-02 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-04 2020-10-02 0000718937 us-gaap:CommonStockMember 2020-07-04 2020-10-02 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-07-04 2020-10-02 0000718937 us-gaap:CommonStockMember 2020-10-02 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-10-02 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-02 0000718937 us-gaap:RetainedEarningsMember 2020-10-02 0000718937 2020-10-02 0000718937 us-gaap:CommonStockMember 2021-01-01 0000718937 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 0000718937 us-gaap:RetainedEarningsMember 2021-01-01 0000718937 us-gaap:RetainedEarningsMember 2021-01-02 2021-10-01 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-02 2021-10-01 0000718937 us-gaap:CommonStockMember 2021-01-02 2021-10-01 0000718937 us-gaap:AdditionalPaidInCapitalMember 2021-01-02 2021-10-01 0000718937 us-gaap:CommonStockMember 2020-01-03 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-01-03 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-03 0000718937 us-gaap:RetainedEarningsMember 2020-01-03 0000718937 2020-01-03 0000718937 us-gaap:RetainedEarningsMember 2020-01-04 2020-10-02 0000718937 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-04 2020-10-02 0000718937 us-gaap:CommonStockMember 2020-01-04 2020-10-02 0000718937 us-gaap:AdditionalPaidInCapitalMember 2020-01-04 2020-10-02 xbrli:pure 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedAccountsPayableMember srt:MaximumMember 2021-01-02 2021-10-01 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedAccountsPayableMember srt:MaximumMember 2020-01-04 2021-01-01 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2021-01-02 2021-10-01 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2021-07-03 2021-10-01 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2020-07-04 2020-10-02 0000718937 us-gaap:SupplierConcentrationRiskMember staa:ConsolidatedPurchasesMember srt:MaximumMember 2020-01-04 2020-10-02 0000718937 staa:PatentsAndLicensesMember 2021-10-01 0000718937 staa:PatentsAndLicensesMember 2021-01-01 iso4217:JPY 0000718937 staa:MizuhoBankMember 2021-10-01 0000718937 staa:MizuhoBankMember 2021-01-02 2021-10-01 0000718937 staa:MizuhoBankMember 2021-01-01 iso4217:CHF 0000718937 staa:CreditSuisseBankMember 2013-09-30 0000718937 staa:CreditSuisseBankMember 2021-01-01 0000718937 staa:CreditSuisseBankMember 2021-01-02 2021-10-01 0000718937 srt:MinimumMember 2021-10-01 0000718937 srt:MaximumMember 2021-10-01 0000718937 us-gaap:MachineryAndEquipmentMember 2021-10-01 0000718937 us-gaap:MachineryAndEquipmentMember 2021-01-01 0000718937 us-gaap:ComputerEquipmentMember 2021-10-01 0000718937 us-gaap:ComputerEquipmentMember 2021-01-01 0000718937 us-gaap:RealEstateMember 2021-10-01 0000718937 us-gaap:RealEstateMember 2021-01-01 0000718937 us-gaap:DomesticCountryMember 2021-01-02 2021-10-01 0000718937 us-gaap:DomesticCountryMember 2020-01-04 2021-01-01 0000718937 us-gaap:StateAndLocalJurisdictionMember 2021-01-02 2021-10-01 0000718937 us-gaap:StateAndLocalJurisdictionMember 2020-01-04 2021-01-01 0000718937 country:US 2021-10-01 0000718937 country:US 2021-01-01 0000718937 staa:SwissPensionPlanMember 2021-07-03 2021-10-01 0000718937 staa:SwissPensionPlanMember 2020-07-04 2020-10-02 0000718937 staa:SwissPensionPlanMember 2021-01-02 2021-10-01 0000718937 staa:SwissPensionPlanMember 2020-01-04 2020-10-02 0000718937 us-gaap:EmployeeStockOptionMember 2021-07-03 2021-10-01 0000718937 us-gaap:EmployeeStockOptionMember 2020-07-04 2020-10-02 0000718937 us-gaap:EmployeeStockOptionMember 2021-01-02 2021-10-01 0000718937 us-gaap:EmployeeStockOptionMember 2020-01-04 2020-10-02 0000718937 us-gaap:RestrictedStockMember 2021-07-03 2021-10-01 0000718937 us-gaap:RestrictedStockMember 2020-07-04 2020-10-02 0000718937 us-gaap:RestrictedStockMember 2021-01-02 2021-10-01 0000718937 us-gaap:RestrictedStockMember 2020-01-04 2020-10-02 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2021-07-03 2021-10-01 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-07-04 2020-10-02 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2021-01-02 2021-10-01 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2020-01-04 2020-10-02 0000718937 us-gaap:PerformanceSharesMember 2021-07-03 2021-10-01 0000718937 us-gaap:PerformanceSharesMember 2020-07-04 2020-10-02 0000718937 us-gaap:PerformanceSharesMember 2021-01-02 2021-10-01 0000718937 us-gaap:PerformanceSharesMember 2020-01-04 2020-10-02 0000718937 staa:NonEmployeeStockOptionsMember 2021-07-03 2021-10-01 0000718937 staa:NonEmployeeStockOptionsMember 2020-07-04 2020-10-02 0000718937 staa:NonEmployeeStockOptionsMember 2021-01-02 2021-10-01 0000718937 staa:NonEmployeeStockOptionsMember 2020-01-04 2020-10-02 0000718937 us-gaap:CostOfSalesMember 2021-07-03 2021-10-01 0000718937 us-gaap:CostOfSalesMember 2020-07-04 2020-10-02 0000718937 us-gaap:CostOfSalesMember 2021-01-02 2021-10-01 0000718937 us-gaap:CostOfSalesMember 2020-01-04 2020-10-02 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-03 2021-10-01 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-04 2020-10-02 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-02 2021-10-01 0000718937 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-04 2020-10-02 0000718937 us-gaap:SellingAndMarketingExpenseMember 2021-07-03 2021-10-01 0000718937 us-gaap:SellingAndMarketingExpenseMember 2020-07-04 2020-10-02 0000718937 us-gaap:SellingAndMarketingExpenseMember 2021-01-02 2021-10-01 0000718937 us-gaap:SellingAndMarketingExpenseMember 2020-01-04 2020-10-02 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-03 2021-10-01 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-04 2020-10-02 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-02 2021-10-01 0000718937 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-04 2020-10-02 0000718937 staa:OmnibusPlanMember 2021-01-02 2021-10-01 0000718937 staa:OmnibusPlanMember us-gaap:EmployeeStockOptionMember 2021-01-02 2021-10-01 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember srt:MinimumMember 2021-01-02 2021-10-01 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember srt:MaximumMember 2021-01-02 2021-10-01 0000718937 staa:OmnibusPlanMember us-gaap:RestrictedStockMember 2021-10-01 0000718937 us-gaap:RestrictedStockMember 2021-01-01 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 0000718937 us-gaap:PerformanceSharesMember 2021-01-01 0000718937 us-gaap:RestrictedStockMember 2021-10-01 0000718937 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 0000718937 us-gaap:PerformanceSharesMember 2021-10-01 0000718937 staa:UnvestedRestrictedStockMember 2021-01-02 2021-10-01 0000718937 staa:UnvestedRestrictedStockMember 2020-01-04 2020-10-02 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2021-07-03 2021-10-01 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-07-04 2020-10-02 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2021-01-02 2021-10-01 0000718937 staa:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-01-04 2020-10-02 0000718937 us-gaap:EmployeeStockOptionMember 2021-07-03 2021-10-01 0000718937 us-gaap:EmployeeStockOptionMember 2020-07-04 2020-10-02 0000718937 us-gaap:EmployeeStockOptionMember 2021-01-02 2021-10-01 0000718937 us-gaap:EmployeeStockOptionMember 2020-01-04 2020-10-02 0000718937 staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2021-07-03 2021-10-01 0000718937 staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2020-07-04 2020-10-02 0000718937 staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2021-01-02 2021-10-01 0000718937 staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2020-01-04 2020-10-02 0000718937 staa:NonConsignmentSalesMember 2021-07-03 2021-10-01 0000718937 staa:NonConsignmentSalesMember 2020-07-04 2020-10-02 0000718937 staa:NonConsignmentSalesMember 2021-01-02 2021-10-01 0000718937 staa:NonConsignmentSalesMember 2020-01-04 2020-10-02 0000718937 staa:ConsignmentSalesMember 2021-07-03 2021-10-01 0000718937 staa:ConsignmentSalesMember 2020-07-04 2020-10-02 0000718937 staa:ConsignmentSalesMember 2021-01-02 2021-10-01 0000718937 staa:ConsignmentSalesMember 2020-01-04 2020-10-02 staa:Country 0000718937 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember staa:OtherCountriesMember srt:MaximumMember 2021-01-02 2021-10-01 0000718937 us-gaap:GeographicDistributionDomesticMember 2021-07-03 2021-10-01 0000718937 us-gaap:GeographicDistributionDomesticMember 2020-07-04 2020-10-02 0000718937 us-gaap:GeographicDistributionDomesticMember 2021-01-02 2021-10-01 0000718937 us-gaap:GeographicDistributionDomesticMember 2020-01-04 2020-10-02 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2021-07-03 2021-10-01 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2020-07-04 2020-10-02 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2021-01-02 2021-10-01 0000718937 country:CN us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-10-02 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2021-07-03 2021-10-01 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2020-07-04 2020-10-02 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2021-01-02 2021-10-01 0000718937 country:JP us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-10-02 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2021-07-03 2021-10-01 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2020-07-04 2020-10-02 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2021-01-02 2021-10-01 0000718937 staa:OtherCountriesMember us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-10-02 0000718937 us-gaap:GeographicDistributionForeignMember 2021-07-03 2021-10-01 0000718937 us-gaap:GeographicDistributionForeignMember 2020-07-04 2020-10-02 0000718937 us-gaap:GeographicDistributionForeignMember 2021-01-02 2021-10-01 0000718937 us-gaap:GeographicDistributionForeignMember 2020-01-04 2020-10-02 0000718937 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember staa:OphthalmicSurgicalProductMember 2021-01-02 2021-10-01 staa:Segment 0000718937 staa:ImplantableCollamerLensesMember 2021-07-03 2021-10-01 0000718937 staa:ImplantableCollamerLensesMember 2020-07-04 2020-10-02 0000718937 staa:ImplantableCollamerLensesMember 2021-01-02 2021-10-01 0000718937 staa:ImplantableCollamerLensesMember 2020-01-04 2020-10-02 0000718937 staa:CataractIntraocularLensesMember 2021-07-03 2021-10-01 0000718937 staa:CataractIntraocularLensesMember 2020-07-04 2020-10-02 0000718937 staa:CataractIntraocularLensesMember 2021-01-02 2021-10-01 0000718937 staa:CataractIntraocularLensesMember 2020-01-04 2020-10-02 0000718937 staa:OtherSurgicalProductsMember 2021-07-03 2021-10-01 0000718937 staa:OtherSurgicalProductsMember 2020-07-04 2020-10-02 0000718937 staa:OtherSurgicalProductsMember 2021-01-02 2021-10-01 0000718937 staa:OtherSurgicalProductsMember 2020-01-04 2020-10-02 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CN 2021-07-03 2021-10-01 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CN 2021-01-02 2021-10-01 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CN 2020-07-04 2020-10-02 0000718937 staa:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CN 2020-01-04 2020-10-02 0000718937 staa:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember country:CN 2021-01-02 2021-10-01 0000718937 staa:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember country:CN 2020-01-04 2021-01-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: October 1, 2021

Or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 0-11634

STAAR SURGICAL COMPANY

(Exact Name of Registrant as Specified in its Charter)

Delaware | 95-3797439
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.)
25651 Atlantic Ocean Drive Lake Forest, California | 92630
(Address of Principal Executive Offices) | (Zip Code)

(626) 303-7902

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common | STAA | NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☑ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The registrant has 47,600,293 shares of common stock, par value $0.01 per share, issued and outstanding as of October 29, 2021.

STAAR SURGICAL COMPANY

INDEX

|  |  | PAGE NUMBER
PART I – FINANCIAL INFORMATION |  | 1
ITEM 1 | FINANCIAL STATEMENTS |  | 1
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |  | 18
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |  | 23
ITEM 4. | CONTROLS AND PROCEDURES |  | 23
PART II – OTHER INFORMATION |  | 24
ITEM 1. | LEGAL PROCEEDINGS |  | 24
ITEM 1A. | RISK FACTORS |  | 24
ITEM 4. | MINE SAFETY DISCLOSURES |  | 24
ITEM 5. | OTHER INFORMATION |  | 24
ITEM 6. | EXHIBITS |  | 25

PART I – FINANCIAL INFORMATION

ITEM 1. | FINANCIAL STATEMENTS

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

(Unaudited)

|  | October 1, 2021 |  |  | January 1, 2021 |
ASSETS |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 196,246 |  |  | $ | 152,453 |
Accounts receivable trade, net of allowance of doubtful accounts of $55 and $59, respectively |  |  | 41,917 |  |  |  | 35,229 |
Inventories, net |  |  | 16,518 |  |  |  | 18,111 |
Prepayments, deposits and other current assets |  |  | 9,264 |  |  |  | 10,625 |
Total current assets |  |  | 263,945 |  |  |  | 216,418 |
Property, plant and equipment, net |  |  | 32,266 |  |  |  | 24,030 |
Finance lease right-of-use assets, net |  |  | 45 |  |  |  | 596 |
Operating lease right-of-use assets, net |  |  | 22,006 |  |  |  | 8,764 |
Intangible assets, net |  |  | 232 |  |  |  | 270 |
Goodwill |  |  | 1,786 |  |  |  | 1,786 |
Deferred income taxes |  |  | 3,700 |  |  |  | 4,944 |
Other assets |  |  | 625 |  |  |  | 608 |
Total assets |  | $ | 324,605 |  |  | $ | 257,416 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Line of credit |  | $ | 1,282 |  |  | $ | 1,379 |
Accounts payable |  |  | 9,092 |  |  |  | 7,874 |
Obligations under finance leases |  |  | 50 |  |  |  | 360 |
Obligations under operating leases |  |  | 2,646 |  |  |  | 2,485 |
Allowance for sales returns |  |  | 5,566 |  |  |  | 4,532 |
Other current liabilities |  |  | 28,160 |  |  |  | 24,606 |
Total current liabilities |  |  | 46,796 |  |  |  | 41,236 |
Obligations under finance leases |  |  | 21 |  |  |  | 38 |
Obligations under operating leases |  |  | 19,437 |  |  |  | 6,537 |
Deferred income taxes |  |  | 222 |  |  |  | 222 |
Asset retirement obligations |  |  | 205 |  |  |  | 221 |
Pension liability |  |  | 8,816 |  |  |  | 11,940 |
Total liabilities |  |  | 75,497 |  |  |  | 60,194 |
Commitments and contingencies |  |  |  |  |  |  |  |
Stockholders’ equity: |  |  |  |  |  |  |  |
Common stock, $0.01 par value; 60,000 shares authorized: 47,599 and 46,448 shares issued and outstanding at October 1, 2021 and January 1, 2021, respectively |  |  | 476 |  |  |  | 464 |
Additional paid-in capital |  |  | 368,572 |  |  |  | 338,194 |
Accumulated other comprehensive loss |  |  | (3,628 | ) |  |  | (5,545 | )
Accumulated deficit |  |  | (116,312 | ) |  |  | (135,891 | )
Total stockholders’ equity |  |  | 249,108 |  |  |  | 197,222 |
Total liabilities and stockholders’ equity |  | $ | 324,605 |  |  | $ | 257,416 |

See accompanying notes to the condensed consolidated financial statements.

1

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts)

(Unaudited)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Net sales |  | $ | 58,352 |  |  | $ | 47,081 |  |  | $ | 171,471 |  |  | $ | 117,462 |
Cost of sales |  |  | 13,051 |  |  |  | 12,210 |  |  |  | 37,825 |  |  |  | 33,401 |
Gross profit |  |  | 45,301 |  |  |  | 34,871 |  |  |  | 133,646 |  |  |  | 84,061 |
Selling, general and administrative expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
General and administrative |  |  | 11,018 |  |  |  | 8,589 |  |  |  | 32,671 |  |  |  | 24,406 |
Selling and marketing |  |  | 18,175 |  |  |  | 12,649 |  |  |  | 50,229 |  |  |  | 34,003 |
Research and development |  |  | 8,271 |  |  |  | 8,751 |  |  |  | 24,790 |  |  |  | 22,960 |
Total selling, general and administrative expenses |  |  | 37,464 |  |  |  | 29,989 |  |  |  | 107,690 |  |  |  | 81,369 |
Operating income |  |  | 7,837 |  |  |  | 4,882 |  |  |  | 25,956 |  |  |  | 2,692 |
Other income (expense), net: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income (expense), net |  |  | (23 | ) |  |  | 1 |  |  |  | (35 | ) |  |  | 237 |
Gain (loss) on foreign currency transactions |  |  | (610 | ) |  |  | 468 |  |  |  | (2,040 | ) |  |  | 388 |
Royalty income |  |  | 185 |  |  |  | 93 |  |  |  | 496 |  |  |  | 239 |
Other expense, net |  |  | (13 | ) |  |  | (63 | ) |  |  | (47 | ) |  |  | (83 | )
Total other income (expense), net |  |  | (461 | ) |  |  | 499 |  |  |  | (1,626 | ) |  |  | 781 |
Income before income taxes |  |  | 7,376 |  |  |  | 5,381 |  |  |  | 24,330 |  |  |  | 3,473 |
Provision for income taxes |  |  | 1,356 |  |  |  | 1,489 |  |  |  | 4,751 |  |  |  | 887 |
Net income |  | $ | 6,020 |  |  | $ | 3,892 |  |  | $ | 19,579 |  |  | $ | 2,586 |
Net income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.13 |  |  | $ | 0.08 |  |  | $ | 0.42 |  |  | $ | 0.06 |
Diluted |  | $ | 0.12 |  |  | $ | 0.08 |  |  | $ | 0.40 |  |  | $ | 0.05 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 47,483 |  |  |  | 45,903 |  |  |  | 47,064 |  |  |  | 45,394 |
Diluted |  |  | 49,592 |  |  |  | 48,180 |  |  |  | 49,448 |  |  |  | 47,589 |

See accompanying notes to the condensed consolidated financial statements.

2

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Net income |  | $ | 6,020 |  |  | $ | 3,892 |  |  | $ | 19,579 |  |  | $ | 2,586 |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Defined benefit plans: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net change in plan assets |  |  | 90 |  |  |  | (334 | ) |  |  | 2,717 |  |  |  | (387 | )
Reclassification into other income (expense), net |  |  | 121 |  |  |  | 70 |  |  |  | 361 |  |  |  | 212 |
Foreign currency translation gain (loss) |  |  | 29 |  |  |  | 316 |  |  |  | (1,198 | ) |  |  | 402 |
Tax effect |  |  | (32 | ) |  |  | (68 | ) |  |  | 37 |  |  |  | (104 | )
Other comprehensive income (loss), net of tax |  |  | 208 |  |  |  | (16 | ) |  |  | 1,917 |  |  |  | 123 |
Comprehensive income |  | $ | 6,228 |  |  | $ | 3,876 |  |  | $ | 21,496 |  |  | $ | 2,709 |

See accompanying notes to the condensed consolidated financial statements.

3

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

|  | Three Months Ended |
|  | Common Stock Shares |  |  | Common Stock Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Compre- hensive Income (Loss) |  |  | Accumulated Deficit |  |  | Total |
Balance, at July 2, 2021 |  |  | 47,391 |  |  | $ | 474 |  |  | $ | 360,316 |  |  | $ | (3,836 | ) |  | $ | (122,332 | ) |  | $ | 234,622 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6,020 |  |  |  | 6,020 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 208 |  |  |  | — |  |  |  | 208 |
Common stock issued upon exercise of options |  |  | 183 |  |  |  | 2 |  |  |  | 4,210 |  |  |  | — |  |  |  | — |  |  |  | 4,212 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 4,046 |  |  |  | — |  |  |  | — |  |  |  | 4,046 |
Vested restricted and performance stock |  |  | 25 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Balance, at October 1, 2021 |  |  | 47,599 |  |  | $ | 476 |  |  | $ | 368,572 |  |  | $ | (3,628 | ) |  | $ | (116,312 | ) |  | $ | 249,108 |
Balance, at July 3, 2020 |  |  | 45,788 |  |  | $ | 458 |  |  | $ | 320,235 |  |  | $ | (2,909 | ) |  | $ | (143,110 | ) |  | $ | 174,674 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,892 |  |  |  | 3,892 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (16 | ) |  |  | — |  |  |  | (16 | )
Common stock issued upon exercise of options |  |  | 269 |  |  |  | 3 |  |  |  | 4,426 |  |  |  | — |  |  |  | — |  |  |  | 4,429 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 3,413 |  |  |  | — |  |  |  | — |  |  |  | 3,413 |
Unvested restricted stock |  |  | 11 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Vested restricted stock |  |  | 4 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Balance, at October 2, 2020 |  |  | 46,072 |  |  | $ | 461 |  |  | $ | 328,074 |  |  | $ | (2,925 | ) |  | $ | (139,218 | ) |  | $ | 186,392 |

See accompanying notes to the condensed consolidated financial statements.

4

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

|  | Nine Months Ended |
|  | Common Stock Shares |  |  | Common Stock Par Value |  |  | Additional Paid-In Capital |  |  | Accumulated Other Compre- hensive Income (Loss) |  |  | Accumulated Deficit |  |  | Total |
Balance, at January 1, 2021 |  |  | 46,448 |  |  | $ | 464 |  |  | $ | 338,194 |  |  | $ | (5,545 | ) |  | $ | (135,891 | ) |  | $ | 197,222 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 19,579 |  |  |  | 19,579 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,917 |  |  |  | — |  |  |  | 1,917 |
Common stock issued upon exercise of options |  |  | 1,089 |  |  |  | 11 |  |  |  | 18,311 |  |  |  | — |  |  |  | — |  |  |  | 18,322 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 12,067 |  |  |  | — |  |  |  | — |  |  |  | 12,067 |
Unvested restricted stock |  |  | 3 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Vested restricted and performance stock |  |  | 59 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |
Balance, at October 1, 2021 |  |  | 47,599 |  |  | $ | 476 |  |  | $ | 368,572 |  |  | $ | (3,628 | ) |  | $ | (116,312 | ) |  | $ | 249,108 |
Balance, at January 3, 2020 |  |  | 44,822 |  |  | $ | 448 |  |  | $ | 304,288 |  |  | $ | (3,048 | ) |  | $ | (141,804 | ) |  | $ | 159,884 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,586 |  |  |  | 2,586 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 123 |  |  |  | — |  |  |  | 123 |
Common stock issued upon exercise of options |  |  | 1,146 |  |  |  | 12 |  |  |  | 13,974 |  |  |  | — |  |  |  | — |  |  |  | 13,986 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 9,812 |  |  |  | — |  |  |  | — |  |  |  | 9,812 |
Unvested restricted stock |  |  | 11 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Vested restricted stock |  |  | 93 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |
Balance, at October 2, 2020 |  |  | 46,072 |  |  | $ | 461 |  |  | $ | 328,074 |  |  | $ | (2,925 | ) |  | $ | (139,218 | ) |  | $ | 186,392 |

See accompanying notes to the condensed consolidated financial statements.

5

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

|  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 19,579 |  |  | $ | 2,586 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Depreciation of property, plant, and equipment |  |  | 2,671 |  |  |  | 2,276 |
Amortization of intangibles |  |  | 26 |  |  |  | 26 |
Deferred income taxes |  |  | 845 |  |  |  | (1,215 | )
Change in net pension liability |  |  | 91 |  |  |  | 522 |
Loss on disposal of property and equipment |  |  | 2 |  |  |  | 3 |
Stock-based compensation expense |  |  | 10,985 |  |  |  | 8,965 |
Provision for sales returns and bad debts |  |  | 1,069 |  |  |  | 815 |
Inventory provision |  |  | 1,097 |  |  |  | 1,195 |
Changes in working capital: |  |  |  |  |  |  |  |
Accounts receivable |  |  | (7,072 | ) |  |  | (10,975 | )
Inventories |  |  | 1,301 |  |  |  | (1,353 | )
Prepayments, deposits, and other current assets |  |  | 1,288 |  |  |  | (636 | )
Accounts payable |  |  | (40 | ) |  |  | (657 | )
Other current liabilities |  |  | 3,622 |  |  |  | (151 | )
Net cash provided by operating activities |  |  | 35,464 |  |  |  | 1,401 |
Cash flows from investing activities: |  |  |  |  |  |  |  |
Acquisition of property and equipment |  |  | (8,956 | ) |  |  | (6,259 | )
Net cash used in investing activities |  |  | (8,956 | ) |  |  | (6,259 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Repayment of finance lease obligations |  |  | (314 | ) |  |  | (455 | )
Repayment on line of credit |  |  | — |  |  |  | (511 | )
Proceeds from the exercise of stock options |  |  | 18,322 |  |  |  | 13,986 |
Proceeds from vested restricted stock |  |  | 1 |  |  |  | 1 |
Net cash provided by financing activities |  |  | 18,009 |  |  |  | 13,021 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  |  | (724 | ) |  |  | 207 |
Increase in cash, cash equivalents and restricted cash |  |  | 43,793 |  |  |  | 8,370 |
Cash and cash equivalents, at beginning of the period |  |  | 152,453 |  |  |  | 119,968 |
Cash and cash equivalents, at end of the period |  | $ | 196,246 |  |  | $ | 128,338 |

See accompanying notes to the condensed consolidated financial statements.

6

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 1 — Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of January 1, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended January 1, 2021.

The Condensed Consolidated Financial Statements for the three and nine months ended October 1, 2021 and October 2, 2020, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and nine months ended October 1, 2021 and October 2, 2020, are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks. Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.

Vendor Concentration

There were no vendors that accounted for over 10% of the Company’s consolidated accounts payable as of October 1, 2021. There was one vendor that accounted for over 10% of the Company’s consolidated accounts payable as of January 1, 2021. There were no vendors that accounted for over 10% of the Company’s consolidated purchases for the three and nine months ended October 1, 2021 and October 2, 2020, respectively.

Use of Estimates

During the COVID-19 pandemic, the Company believes it has used reasonable estimates and assumptions in determining valuation allowances for uncollectible trade receivables, sales returns reserves, obsolete and excess inventory reserves, deferred income taxes, and tax reserves, including valuation allowances for deferred tax assets, pension liabilities, evaluation of asset impairment, in determining the useful life of depreciable and definite-lived intangible assets, and in the variables and assumptions used to calculate and record stock-based compensation. Throughout the COVID-19 pandemic the Company offered extended payment terms to assist its surgeon customers and their clinics as they resumed business. Although the Company experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic in the first half of 2020, the Company experienced improvements since the third quarter of 2020 as elective refractive surgeries resumed. The Company is unaware of any material impairment of customer receivables. The Company’s sales representatives throughout the world remain engaged with customers conducting online training and other educational courses which have been very well attended. This activity has given the Company insight into COVID-19’s impact on customers and potential impairment of receivables.

Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted

On January 1, 2021 (beginning of fiscal year 2021), the Company adopted Accounting Standards Update (“ASU”) 2019‑12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which removes the following exceptions: exception to the incremental approach for intraperiod tax allocation; exception to accounting for basis differences when there are ownership changes in foreign investments; and exception to interim period tax accounting for year to date losses that exceed anticipated losses. ASU 2019-12 also improves financial reporting for franchise taxes that are partially based on income; transactions with a government that result in a step up in the tax basis of goodwill; separate financial statements of legal entities that are not subject to tax; and enacted changes in tax laws in interim periods. The adoption of ASU 2019-12 did not have a material impact on the Condensed Consolidated Financial Statements.

7

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 2 — Inventories

Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Raw materials and purchased parts |  | $ | 3,487 |  |  | $ | 3,679 |
Work in process |  |  | 3,236 |  |  |  | 2,174 |
Finished goods |  |  | 10,943 |  |  |  | 13,717 |
Total inventories, gross |  |  | 17,666 |  |  |  | 19,570 |
Less inventory reserves |  |  | (1,148 | ) |  |  | (1,459 | )
Total inventories, net |  | $ | 16,518 |  |  | $ | 18,111 |

Note 3 — Prepayments, Deposits, and Other Current Assets

Prepayments, deposits, and other current assets consisted of the following (in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Prepayments and deposits |  | $ | 4,217 |  |  | $ | 3,423 |
Prepaid insurance |  |  | 884 |  |  |  | 2,677 |
Prepaid marketing |  |  | 851 |  |  |  | 368 |
Consumption tax receivable |  |  | 556 |  |  |  | 1,409 |
Value added tax (VAT) receivable |  |  | 1,062 |  |  |  | 2,056 |
Other(1) |  |  | 1,694 |  |  |  | 692 |
Total prepayments, deposits and other current assets |  | $ | 9,264 |  |  | $ | 10,625 |

(1) | No individual item in “other current assets” exceeds 5% of the total prepayments, deposits and other current assets.

Note 4 — Property, Plant and Equipment

Property, plant and equipment, net consisted of the following (in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Machinery and equipment |  | $ | 23,880 |  |  | $ | 21,209 |
Computer equipment and software |  |  | 8,712 |  |  |  | 7,423 |
Furniture and fixtures |  |  | 4,741 |  |  |  | 4,676 |
Leasehold improvements |  |  | 11,743 |  |  |  | 11,388 |
Construction in process |  |  | 17,654 |  |  |  | 11,120 |
Total property, plant and equipment, gross |  |  | 66,730 |  |  |  | 55,816 |
Less accumulated depreciation |  |  | (34,464 | ) |  |  | (31,786 | )
Total property, plant and equipment, net |  | $ | 32,266 |  |  | $ | 24,030 |

Note 5 –Intangible Assets

Intangible assets, net consisted of the following (in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Long-lived amortized intangible assets |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |
Patents and licenses |  | $ | 9,336 |  |  | $ | (9,104 | ) |  | $ | 232 |  |  | $ | 9,382 |  |  | $ | (9,112 | ) |  | $ | 270 |

8

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 6 – Other Current Liabilities

Other current liabilities consisted of the following (in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Accrued salaries and wages |  | $ | 11,176 |  |  | $ | 7,074 |
Accrued bonuses |  |  | 5,167 |  |  |  | 3,000 |
Accrued insurance |  |  | 90 |  |  |  | 2,633 |
Income taxes payable |  |  | 3,685 |  |  |  | 4,657 |
Accrued consumption tax |  |  | 1,034 |  |  |  | 1,743 |
Marketing obligations |  |  | 1,933 |  |  |  | 1,484 |
Other(1) |  |  | 5,075 |  |  |  | 4,015 |
Total other current liabilities |  | $ | 28,160 |  |  | $ | 24,606 |

(1) | No individual item in “Other” exceeds 5% of the other current liabilities.

Note 7 – Lines of Credit

Since 1998, the Company’s wholly owned Japanese subsidiary, STAAR Japan, has had an agreement with Mizuho Bank which provides for borrowings of up to 500,000,000 Yen, at an interest rate equal to the uncollateralized overnight call rate (approximately 0.05% as of October 1, 2021) plus a 0.50% spread, and may be renewed quarterly (the current line expires on November 21, 2021). The credit facility is not collateralized. The Company had 142,500,000 Yen outstanding on the line of credit as of October 1, 2021 and January 1, 2021 (approximately $1,282,000 and $1,379,000 based on the foreign exchange rates on October 1, 2021 and January 1, 2021, respectively), which approximates fair value due to the short-term maturity and market interest rates of the line of credit. In case of default, the interest rate will be increased to 14% per annum. There was 357,500,000 Yen available for borrowing as of October 1, 2021 and January 1, 2021 (approximately $3,217,000 and $3,459,000 based on the foreign exchange rate on October 1, 2021 and January 1, 2021, respectively). Given the Company’s existing cash resources, at maturity on November 21, 2021, the Company expects to repay this credit facility in full.

In September 2013, the Company’s wholly owned Swiss subsidiary, STAAR Surgical AG, entered into a framework agreement for loans (“framework agreement”) with Credit Suisse (the “Bank”). The framework agreement provides for borrowings of up to 1,000,000 CHF (Swiss Francs) (approximately $1,100,000 at the rate of exchange on January 1, 2021), to be used for working capital purposes. Accrued interest and 0.25% commissions on average outstanding borrowings is payable quarterly and the interest rate will be determined by the Bank based on the then prevailing market conditions at the time of borrowing. The framework agreement is automatically renewed on an annual basis based on the same terms assuming there is no default. The framework agreement may be terminated by either party at any time in accordance with its general terms and conditions. The framework agreement is not collateralized and contains certain conditions such as providing the Bank with audited financial statements annually and notice of significant events or conditions, as defined in the framework agreement. The Bank may also declare all amounts outstanding to be immediately due and payable upon a change of control or a “material qualification” in STAAR Surgical independent auditors’ report, as defined. There were no borrowings outstanding as of January 1, 2021. Given its immaterial nature and the Company’s existing cash resources, during the second quarter of 2021, the Company cancelled the framework agreement.

The Company is in compliance with covenants of its credit facility as of October 1, 2021.

9

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 8 – Leases

Finance Leases

The Company entered into finance leases primarily related to purchases of equipment used for manufacturing or computer-related equipment. These finance leases are two to five years in length and have fixed payment amounts for the term of the contract and have options to purchase the assets at the end of the lease term. Supplemental balance sheet information related to finance leases consisted of the following (dollars in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Machinery and equipment |  | $ | 36 |  |  | $ | 570 |
Computer equipment and software |  |  | 557 |  |  |  | 806 |
Finance lease right-of-use assets, gross |  |  | 593 |  |  |  | 1,376 |
Less accumulated depreciation |  |  | (548 | ) |  |  | (780 | )
Finance lease right-of-use assets, net |  | $ | 45 |  |  | $ | 596 |
Total finance lease liability |  | $ | 71 |  |  | $ | 398 |
Weighted-average remaining lease term (in years) |  |  | 1.4 |  |  |  | 0.9 |
Weighted-average discount rate |  |  | 1.65 | % |  |  | 3.46 | %

Supplemental cash flow information related to finance leases consisted of the following (dollars in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Amortization of finance lease right-of-use asset |  | $ | 15 |  |  | $ | 48 |  |  | $ | 71 |  |  | $ | 215 |
Interest on finance lease liabilities |  |  | 1 |  |  |  | 7 |  |  |  | 6 |  |  |  | 25 |
Cash paid for amounts included in the measurement of finance lease liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating cash flows |  |  | 1 |  |  |  | 7 |  |  |  | 6 |  |  |  | 25 |
Financing cash flows |  |  | 36 |  |  |  | 109 |  |  |  | 314 |  |  |  | 455 |
Right-of-use assets obtained in exchange for new finance lease liabilities |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 22 |

Operating Leases

The Company entered into operating leases primarily related to real property (office, manufacturing and warehouse facilities), automobiles and copiers. These operating leases are two to ten years in length with options to extend. The Company does not include any lease extensions in the initial valuation unless the Company was reasonably certain to extend the lease. Depending on the lease, there are those with fixed payment amounts for the entire length of the contract or payments which increase periodically as noted in the contract or increased at an inflation rate indicator. For operating leases that increase using an inflation rate indicator, the Company used the inflation rate at the time the lease was entered into for the length of the lease term. Supplemental balance sheet information related to operating leases consisted of the following (dollars in thousands):

|  | October 1, 2021 |  |  | January 1, 2021 |
Machinery and equipment |  | $ | 787 |  |  | $ | 860 |
Computer equipment and software |  |  | 472 |  |  |  | 462 |
Real property |  |  | 25,185 |  |  |  | 12,956 |
Operating lease right-of-use assets, gross |  |  | 26,444 |  |  |  | 14,278 |
Less accumulated depreciation |  |  | (4,438 | ) |  |  | (5,514 | )
Operating lease right-of-use assets, net |  | $ | 22,006 |  |  | $ | 8,764 |
Total operating lease liability |  | $ | 22,083 |  |  | $ | 9,022 |
Weighted-average remaining lease term (in years) |  |  | 8.9 |  |  |  | 5.2 |
Weighted-average discount rate |  |  | 3.23 | % |  |  | 2.61 | %

10

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 8 – Leases (Continued)

Operating Leases (Continued)

Supplemental cash flow information related to operating leases was as follows (dollars in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Operating lease cost |  | $ | 931 |  |  | $ | 752 |  |  | $ | 2,571 |  |  | $ | 2,238 |
Cash paid for amounts included in the measurement of operating lease liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating cash flows |  |  | 846 |  |  |  | 780 |  |  |  | 2,432 |  |  |  | 2,281 |
Right-of-use assets obtained in exchange for new operating lease liabilities |  |  | 15,212 |  |  |  | 2,842 |  |  |  | 19,219 |  |  |  | 3,160 |

Future Minimum Lease Commitments

Estimated future minimum lease payments under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of October 1, 2021 is as follows (in thousands):

As of October 1, 2021 12 Months Ended |  | Operating Leases |  |  | Finance Leases |
September 2022 |  | $ | 3,329 |  |  | $ | 51 |
September 2023 |  |  | 3,337 |  |  |  | 14 |
September 2024 |  |  | 2,797 |  |  |  | 7 |
September 2025 |  |  | 2,365 |  |  |  | — |
September 2026 |  |  | 2,244 |  |  |  | — |
Thereafter |  |  | 11,826 |  |  |  | — |
Total minimum lease payments, including interest |  | $ | 25,898 |  |  | $ | 72 |
Less amounts representing interest |  |  | (3,815 | ) |  |  | (1 | )
Total minimum lease payments |  | $ | 22,083 |  |  | $ | 71 |

Note 9 — Income Taxes

The Company recorded an income tax provision (benefit) as follows (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Provision for income taxes |  | $ | 1,356 |  |  | $ | 1,489 |  |  | $ | 4,751 |  |  | $ | 887 |

The Company recorded income taxes of $1,356,000 and $4,751,000 for the three and nine months ended October 1, 2021, respectively, due to pre-tax income generated in certain foreign jurisdictions and, for the nine months ended October 1, 2021, a recapture of its U.S. valuation allowance of $845,000 as a result of increased tax deductions in the projection of taxable income used in its valuation assessment. The Company, from time to time may adjust the projections of taxable income as a result of current conditions. The Company recorded income taxes of $1,489,000 for the three months ended October 2, 2020, due to pre-tax income generated in certain foreign jurisdictions, partially offset by a reversal of $154,000 of its U.S. valuation allowance, as a result of an increase in foreign income and changes in the usage and release of certain deferred tax assets. The Company recorded an income taxes of $887,000 for the nine months ended October 2, 2020 due to pre-tax income generated in certain foreign jurisdictions, partially offset by a release of its U.S. valuation allowance of $1,215,000, as a result of the Company revising its global forecasts in response to the impacts of COVID‑19, and due to changes in the usage and release of certain deferred tax assets. The Company’s quarterly provision for income taxes is determined by estimating an annual effective tax rate. This estimate may fluctuate throughout the year as new information becomes available affecting its underlying assumptions. There are no unrecognized tax benefits related to uncertain tax positions taken by the Company. All earnings from the Company’s subsidiaries are not considered to be permanently reinvested.

11

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 9 — Income Taxes (Continued)

The 2017 Tax Act subjects a U.S. shareholder to tax on Global Intangible Low Tax Income (“GILTI”) earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50 percent of GILTI, however this deduction is limited by the Company’s U.S. taxable income. The Company has elected to account for GILTI as a current period expense when incurred.

Final regulations issued on July 20, 2020 allow companies to exclude certain high-taxed income from their GILTI calculation (the GILTI high-tax exclusion). The GILTI high-tax exclusion applies if the effective foreign tax rate is 90% or more of the rate that would apply if the income were subject to the maximum US rate of tax specified in section 11 (currently 18.9%, based on a maximum rate of 21%). The final regulations also provide that the GILTI high-tax exclusion is an annual election made each year and is retroactive to years beginning after December 31, 2017. The Company has made the election to exclude certain high-taxed income from its GILTI calculation for the three and nine months ended October 1, 2021 and October 2, 2020, respectively.

The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. In evaluating the Company’s ability to recover its deferred tax assets, management considers among other things, projected future income, tax planning strategies and all other available positive and negative evidence in making this assessment. The “incremental cash tax savings approach” is further described in Notes 1 and 10 of the Company’s fiscal 2020 Form 10-K. Under the incremental cash tax savings approach, the Company’s cumulative valuation allowance recorded was $38,377,000 and $8,089,000 for federal and state, respectively, at October 1, 2021, and $34,681,000 and $7,399,000 for federal and state, respectively, at January 1, 2021. Under the incremental cash tax savings approach, the valuation allowance recorded reflects the net operating losses and deferred tax assets which will not result in future cash tax savings and therefore provide no additional benefit. Total U.S. net deferred tax assets were $3,026,000 and $3,870,000 as of October 1, 2021 and January 1, 2021, respectively.

Note 10 – Defined Benefit Pension Plans

The Company has defined benefit plans covering employees of its Switzerland and Japan operations. The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Service cost(1) |  | $ | 326 |  |  | $ | 320 |  |  | $ | 1,003 |  |  | $ | 959 |
Interest cost(2) |  |  | 14 |  |  |  | 12 |  |  |  | 42 |  |  |  | 34 |
Expected return on plan assets(2) |  |  | (99 | ) |  |  | (47 | ) |  |  | (299 | ) |  |  | (136 | )
Prior service credit(2),(3) |  |  | (10 | ) |  |  | (9 | ) |  |  | (32 | ) |  |  | (26 | )
Actuarial loss recognized in current period(2),(3) |  |  | 131 |  |  |  | 79 |  |  |  | 393 |  |  |  | 238 |
Net periodic pension cost |  | $ | 362 |  |  | $ | 355 |  |  | $ | 1,107 |  |  | $ | 1,069 |

(1) | Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Income.

(2) | Recognized in other income (expense), net on the Condensed Consolidated Statements of Income.

(3) | Amounts reclassified from accumulated other comprehensive income (loss).

The Company currently is not required to and does not make contributions to its Japan pension plan. The Company’s contributions to its Swiss pension plan are as follows (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Employer contribution |  | $ | 204 |  |  | $ | 189 |  |  | $ | 601 |  |  | $ | 519 |

12

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 11 — Stockholders’ Equity

Stock-Based Compensation

The cost that has been charged against income for stock-based compensation is set forth below (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Employee stock options |  | $ | 2,594 |  |  | $ | 2,469 |  |  | $ | 7,850 |  |  | $ | 7,206 |
Restricted stock |  |  | 109 |  |  |  | 119 |  |  |  | 507 |  |  |  | 273 |
Restricted stock units |  |  | 700 |  |  |  | 415 |  |  |  | 2,048 |  |  |  | 1,238 |
Performance stock units |  |  | 124 |  |  |  | 54 |  |  |  | 325 |  |  |  | 54 |
Nonemployee stock options |  |  | 136 |  |  |  | 69 |  |  |  | 255 |  |  |  | 194 |
Total stock-based compensation expense |  | $ | 3,663 |  |  | $ | 3,126 |  |  | $ | 10,985 |  |  | $ | 8,965 |

The Company recorded stock-based compensation costs in the following categories (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Cost of sales |  | $ | 61 |  |  | $ | 30 |  |  | $ | 150 |  |  | $ | 82 |
General and administrative |  |  | 1,671 |  |  |  | 1,307 |  |  |  | 4,925 |  |  |  | 3,601 |
Selling and marketing |  |  | 851 |  |  |  | 807 |  |  |  | 2,637 |  |  |  | 2,674 |
Research and development |  |  | 1,080 |  |  |  | 982 |  |  |  | 3,273 |  |  |  | 2,608 |
Total stock-based compensation expense, net |  |  | 3,663 |  |  |  | 3,126 |  |  |  | 10,985 |  |  |  | 8,965 |
Amounts capitalized as part of inventory |  |  | 383 |  |  |  | 287 |  |  |  | 1,082 |  |  |  | 847 |
Total stock-based compensation expense, gross |  | $ | 4,046 |  |  | $ | 3,413 |  |  | $ | 12,067 |  |  | $ | 9,812 |

Incentive Plan

The Amended and Restated Omnibus Equity Incentive Plan (“the Plan”) provides for various forms of stock-based incentives. To date, of the available forms of awards under the Plan, the Company has granted only stock options, restricted stock, unrestricted share grants, restricted stock units (“RSUs”) and performance stock units (“PSUs”). Options under the Plan are granted at fair market value on the date of grant, become exercisable generally over a three-year period, or as determined by the Board of Directors, and expire over periods not exceeding 10 years from the date of grant. Certain option and share awards provide for accelerated vesting if there is a change in control and pre-established financial metrics are met (as defined in the Plan). Grants of restricted stock outstanding under the Plan generally vest over periods of one to three years. Grants of RSUs and PSUs outstanding under the Plan generally vest based on service, performance, or a combination of both. As of October 1, 2021, there were 3,002,026 shares available for grant under the Plan.

Assumptions

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of options granted is derived from the historical exercises and post-vesting cancellations and represents the period of time that options granted are expected to be outstanding. The Company has calculated a 6% estimated forfeiture rate based on historical forfeiture experience. The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant.

13

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 11 — Stockholders’ Equity (Continued)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Expected dividend yield |  |  | 0 | % |  |  | 0 | % |  |  | 0 | % |  |  | 0 | %
Expected volatility |  |  | 53 | % |  |  | 53 | % |  |  | 53 | % |  |  | 53 | %
Risk-free interest rate |  |  | 0.79 | % |  |  | 0.31 | % |  |  | 0.84 | % |  |  | 0.53 | %
Expected term (in years) |  |  | 5.38 |  |  |  | 5.72 |  |  |  | 5.38 |  |  |  | 5.72 |

Stock Options

A summary of stock option activity under the Plan for nine months ended October 1, 2021 is presented below:

|  | Stock Options (in 000’s) |  |  | Minimum Exercise Price |  |  | Maximum Exercise Price |
Outstanding at January 1, 2021 |  |  | 3,418 |  |  |  |  |  |  |  |  |
Granted |  |  | 268 |  |  |  |  |  |  |  |  |
Exercised |  |  | (1,089 | ) |  |  |  |  |  |  |  |
Forfeited or expired |  |  | (27 | ) |  |  |  |  |  |  |  |
Outstanding at October 1, 2021 |  |  | 2,570 |  |  | $ | 5.34 |  |  | $ | 154.96 |
Exercisable at October 1, 2021 |  |  | 1,864 |  |  |  |  |  |  |  |  |

Restricted Stock, Restricted Stock Units and Performance Stock Units

A summary of restricted stock, RSUs and PSUs activity under the Plan for the nine months ended October 1, 2021 is presented below (shares in thousands):

|  | Restricted Stock |  |  | RSUs |  |  | PSUs |
Unvested at January 1, 2021 |  |  | 11 |  |  |  | 122 |  |  |  | 15 |
Granted |  |  | 3 |  |  |  | 63 |  |  |  | — |
Vested |  |  | (11 | ) |  |  | (54 | ) |  |  | (5 | )
Forfeited or expired |  |  | — |  |  |  | — |  |  |  | — |
Unvested at October 1, 2021 |  |  | 3 |  |  |  | 131 |  |  |  | 10 |

Note 12 - Commitments and Contingencies

Litigation and Claims

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business. These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability. STAAR maintains insurance coverage for various matters, including product liability and certain securities claims. While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all its assets, or termination “without cause or for good reason” as defined in the employment agreements.

14

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 13 — Basic and Diluted Net Income Per Share

The following table sets forth the computation of basic and diluted net income per share (in thousands except per share amounts):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 6,020 |  |  | $ | 3,892 |  |  | $ | 19,579 |  |  | $ | 2,586 |
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common shares outstanding |  |  | 47,486 |  |  |  | 45,914 |  |  |  | 47,067 |  |  |  | 45,405 |
Less: Unvested restricted stock |  |  | (3 | ) |  |  | (11 | ) |  |  | (3 | ) |  |  | (11 | )
Denominator for basic calculation |  |  | 47,483 |  |  |  | 45,903 |  |  |  | 47,064 |  |  |  | 45,394 |
Weighted average effects of potentially diluted common stock: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 2,013 |  |  |  | 2,208 |  |  |  | 2,277 |  |  |  | 2,124 |
Unvested restricted stock |  |  | — |  |  |  | — |  |  |  | 6 |  |  |  | 5 |
RSUs |  |  | 86 |  |  |  | 68 |  |  |  | 90 |  |  |  | 66 |
PSUs |  |  | 10 |  |  |  | 1 |  |  |  | 11 |  |  |  | — |
Denominator for diluted calculation |  |  | 49,592 |  |  |  | 48,180 |  |  |  | 49,448 |  |  |  | 47,589 |
Net income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.13 |  |  | $ | 0.08 |  |  | $ | 0.42 |  |  | $ | 0.06 |
Diluted |  | $ | 0.12 |  |  | $ | 0.08 |  |  | $ | 0.40 |  |  | $ | 0.05 |

The following table sets forth (in thousands) the weighted average number of options to purchase shares of common stock, restricted stock, RSUs and PSUs with either exercise prices or unrecognized compensation cost per share greater than the average market price per share of the Company’s common stock, which were not included in the calculation of diluted per share amounts because the effects would be anti-dilutive.

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Stock options |  |  | 33 |  |  |  | 12 |  |  |  | 201 |  |  |  | 896 |
Restricted stock, RSUs and PSUs |  |  | 6 |  |  |  | 8 |  |  |  | 3 |  |  |  | 13 |
Total |  |  | 39 |  |  |  | 20 |  |  |  | 204 |  |  |  | 909 |

15

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 14 — Disaggregation of Sales, Geographic Sales and Product Sales

In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data. The following breaks down sales into the following categories (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Non-consignment sales |  | $ | 53,819 |  |  | $ | 42,535 |  |  | $ | 156,604 |  |  | $ | 96,381 |
Consignment sales |  |  | 4,533 |  |  |  | 4,546 |  |  |  | 14,867 |  |  |  | 21,081 |
Total net sales |  | $ | 58,352 |  |  | $ | 47,081 |  |  | $ | 171,471 |  |  | $ | 117,462 |

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Domestic |  | $ | 2,385 |  |  | $ | 1,477 |  |  | $ | 7,429 |  |  | $ | 4,098 |
Foreign: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
China |  |  | 28,411 |  |  |  | 23,301 |  |  |  | 80,984 |  |  |  | 53,619 |
Japan |  |  | 10,488 |  |  |  | 9,208 |  |  |  | 29,374 |  |  |  | 24,973 |
Other(1) |  |  | 17,068 |  |  |  | 13,095 |  |  |  | 53,684 |  |  |  | 34,772 |
Total foreign sales |  |  | 55,967 |  |  |  | 45,604 |  |  |  | 164,042 |  |  |  | 113,364 |
Total net sales |  | $ | 58,352 |  |  | $ | 47,081 |  |  | $ | 171,471 |  |  | $ | 117,462 |

(1) | No other location individually exceeds 10% of the total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line was as follows (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
ICLs |  | $ | 54,153 |  |  | $ | 41,493 |  |  | $ | 159,889 |  |  | $ | 101,561 |
Other product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cataract IOLs |  |  | 2,525 |  |  |  | 3,325 |  |  |  | 9,324 |  |  |  | 9,880 |
Other surgical products |  |  | 1,674 |  |  |  | 2,263 |  |  |  | 2,258 |  |  |  | 6,021 |
Total other product sales |  |  | 4,199 |  |  |  | 5,588 |  |  |  | 11,582 |  |  |  | 15,901 |
Total net sales |  | $ | 58,352 |  |  | $ | 47,081 |  |  | $ | 171,471 |  |  | $ | 117,462 |

One customer, the Company’s distributor in China, accounted for 49% and 47% of net sales for the three and nine months ended October 1, 2021 and the same customer, accounted for 49% and 46% for the three and nine months ended October 2, 2020, respectively. As of October 1, 2021 and January 1, 2021, respectively, one customer, the Company’s distributor in China, accounted for 47% and 46% of consolidated trade receivables.

16

STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

Note 15 — COVID-19 and CARES Act Developments

In December 2019, COVID-19 surfaced and in March 2020, the World Health Organization declared a pandemic related to the rapid spread of COVID-19 around the world. The impact of the COVID-19 outbreak on the businesses and the economy in the U.S. and the rest of the world is, and is expected to continue to be, uncertain and may continue to be significant. Accordingly, the Company cannot predict the extent to which its financial condition and results of operation will be affected. On March 17, 2020, the Company suspended most of its production and non-essential business locations where employees can work from home. A very limited number of manufacturing personnel remained at work for critical late staged processes, until the end of March 2020. Manufacturing resumed on April 27, 2020. The Company’s revenues have been adversely impacted, and the Company experienced a substantial slowdown in sales beginning March 20, 2020 in global geographies characterized as “hot spots” for the COVID-19 virus, including parts of Europe, North America, Asia, the Middle East and India. In certain of these markets, sales have paused as elective surgeries are discouraged to support COVID-19 related needs. The Company expects decreases in sales in certain geographies to continue in 2021 as different geographies resume business activities on differing timelines.

The Coronavirus Aid, Relief and Economic Security (“CARES”) Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company did not apply for or require financing available under the CARES Act and does not expect to do so. The Company will continue to monitor the impact that the CARES Act may have on its business, financial condition, results of operations, or liquidity.

The Consolidated Appropriations Act (“CAA”) among other things, opened up another round of Paycheck Protection Program loans, expanding eligibility to small nonprofits, destination marking organizations, and housing cooperatives, provided additional funding for the Economic Injury Disaster Loans and grants, extends the Employee Retention Tax Credit, also extended and expanded Paid Sick and Family Leave Credits and the Employee Social Security tax deferral. The Company will continue to monitor the impact that the CAA may have on its business, financial condition, results of operations, or liquidity.

17

ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe,” “will,” “should,” “forecast” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements about any of the following: any projections of or guidance as to earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the expected impact of the COVID-19 pandemic and related public health measures (including but not limited to their impact on sales, operations or clinical trials globally), the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products (including the EVO family of lenses in the U.S. and the EVO Viva family of lenses for presbyopia internationally); commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving 2021 and 2022 business plans; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and we can give no assurance that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described in in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 24, 2021. We undertake no obligation to update these forward-looking statements after the date of this report to reflect future events or circumstances or to reflect actual outcomes.

The following discussion should be read in conjunction with the audited consolidated financial statements of STAAR, including the related notes, provided in this report.

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye. We are the world’s leading manufacturer of intraocular lenses for patients seeking refractive vision correction, and we also make lenses for use in surgery to treat cataracts. All the lenses we make are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Refractive surgery is performed to treat the type of visual disorders that have traditionally been corrected using eyeglasses or contact lenses. We refer to our lenses used in refractive surgery as “implantable Collamer® lenses” or “ICLs.” The field of refractive surgery includes both lens-based procedures, using products like our ICL family of products, and laser-based procedures like LASIK. Successful refractive surgery can correct common vision disorders such as myopia, hyperopia, and astigmatism. Cataract surgery is a common outpatient procedure where the eye’s natural lens that has become cloudy with age is removed and replaced with an artificial lens called an intraocular lens (“IOL”) to restore the patient’s vision. STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We position our cataract IOL lenses used in surgery that treats cataracts based on quality and value.

Recent Developments

Orders for ICLs outstripped our supply of lenses in the quarter. With China being our largest market, our distributor’s inventory levels in China were drawn down to historically low levels to meet surgeon and patient demand. While we were able to meet 35% growth levels to the surgeon and patient community from our distributor inventory, we were only able to ship units equaling 19% growth to our distributor. COVID-related employment, production output and modest supply chain challenges impacted the quarter and resulted in a backlog of over 20,000 lenses at the end of the third quarter representing several million dollars of orders-in-house. Despite the challenges which we are addressing, we achieved global ICL unit growth up 29%, year over year, for the third quarter of 2021. ICL unit growth was up 44% in Japan, up 21% in South Korea, up 338% in India, up 25% in Germany, up 66% in the U.S. and up 32% in our hybrid distributor markets. In the U.S. our submission of clinical data for STAAR’s EVO ICL family of myopia lenses remains under customary interactive FDA review. While a formal written response from the FDA has now extended beyond the late October date implied by MDUFA IV performance goals for PMA supplements, we see nothing unusual related to our current process with the FDA at this time.

18

Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Income discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the nine months ended October 1, 2021 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended January 1, 2021.

Results of Operations

The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.

|  | Percentage of Net Sales for Three Months |  |  | Percentage of Net Sales for Nine Months |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |
Net sales |  |  | 100.0 | % |  |  | 100.0 | % |  |  | 100.0 | % |  |  | 100.0 | %
Cost of sales |  |  | 22.4 | % |  |  | 25.9 | % |  |  | 22.1 | % |  |  | 28.4 | %
Gross profit |  |  | 77.6 | % |  |  | 74.1 | % |  |  | 77.9 | % |  |  | 71.6 | %
General and administrative |  |  | 18.9 | % |  |  | 18.2 | % |  |  | 19.0 | % |  |  | 20.8 | %
Selling and marketing |  |  | 31.1 | % |  |  | 26.9 | % |  |  | 29.3 | % |  |  | 29.0 | %
Research and development |  |  | 14.2 | % |  |  | 18.6 | % |  |  | 14.5 | % |  |  | 19.5 | %
Total selling, general and administrative |  |  | 64.2 | % |  |  | 63.7 | % |  |  | 62.8 | % |  |  | 69.3 | %
Operating income |  |  | 13.4 | % |  |  | 10.4 | % |  |  | 15.1 | % |  |  | 2.3 | %
Total other income (expense), net |  |  | (0.8 | )% |  |  | 1.1 | % |  |  | (0.9 | )% |  |  | 0.7 | %
Income before income taxes |  |  | 12.6 | % |  |  | 11.5 | % |  |  | 14.2 | % |  |  | 3.0 | %
Provision for income taxes |  |  | 2.3 | % |  |  | 3.2 | % |  |  | 2.8 | % |  |  | 0.8 | %
Net income |  |  | 10.3 | % |  |  | 8.3 | % |  |  | 11.4 | % |  |  | 2.2 | %

Net Sales

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
ICLs |  | $ | 54,153 |  |  | $ | 41,493 |  |  |  | 30.5 | % |  | $ | 159,889 |  |  | $ | 101,561 |  |  |  | 57.4 | %
Other product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cataract IOLs |  |  | 2,525 |  |  |  | 3,325 |  |  |  | (24.1 | )% |  |  | 9,324 |  |  |  | 9,880 |  |  |  | (5.6 | )%
Other surgical products |  |  | 1,674 |  |  |  | 2,263 |  |  |  | (26.0 | )% |  |  | 2,258 |  |  |  | 6,021 |  |  |  | (62.5 | )%
Total other product sales |  |  | 4,199 |  |  |  | 5,588 |  |  |  | (24.9 | )% |  |  | 11,582 |  |  |  | 15,901 |  |  |  | (27.2 | )%
Net sales |  | $ | 58,352 |  |  | $ | 47,081 |  |  |  | 23.9 | % |  | $ | 171,471 |  |  | $ | 117,462 |  |  |  | 46.0 | %

Net sales for the three months ended October 1, 2021 were $58.4 million, an increase of 24% from $47.1 million reported during the same period of 2020. The increase in net sales was due to increased ICL sales of $12.7 million, partially offset by a decrease in other product sales of $1.4 million. Changes in foreign currency unfavorably impacted net sales by $0.2 million.

19

Net sales for the nine months ended October 1, 2021 were $171.5 million, a n in crease of 46% from $117.5 million report ed during the same period of 2020. The in crease in net sales was due to in crease d ICL sales of $58.3 million, partially offset by a decrease in other product sales of $4.3 million. Changes in foreign currency favorably impacted net sales by $1.7 million.

Total ICL sales for the three months ended October 1, 2021 were $54.2 million, an increase of 31% from $41.5 million reported for the same period of 2020, with unit increase of 29%. The APAC region sales increased by 28%, with unit growth up 25%, due to sales growth in India up 348%, Japan up 42%, Korea up 23%, China up 22%, and other APAC Distributors up 18%. The Europe, Middle East, Africa and Latin America region sales increased 37% with unit increase of 51%, due to sales growth in Middle East and North Africa up 156%, Latin America up 46%, United Kingdom up 45%, Distributor Operations up 30% and Germany up 26% and Spain up 13%. The North America region sales increased 40%, with unit increase of 50%, due to sales growth in the U.S. up 50%. Changes in foreign currency unfavorably impacted ICL sales by $0.1 million for the three months ended October 1, 2021. ICL sales represented 92.8% and 88.1% of our total sales for the three months ended October 1, 2021 and October 2, 2020, respectively.

Total ICL sales for the nine months ended October 1, 2021 were $159.9 million, an increase of 57% from $101.6 million reported for the same period of 2020, with unit increase of 52%. The APAC region sales increased by 54%, with unit growth up 48%, due to sales growth in India up 158%, Japan up 66%, China up 51%, other APAC Distributors up 49%, and Korea up 36%. The Europe, Middle East, Africa and Latin America region sales increased 66% with unit increase of 68%, due to sales growth in the Middle East and North Africa up 117%, United Kingdom up 97%, Latin America up 81%, Distributor Operations up 62%, Spain up 59% and Germany up 51%. The North America region sales increased 82%, with unit increase of 94%, due to sales growth in the U.S. up 84% and Canada up 71%. Changes in foreign currency favorably impacted ICL sales by $1.6 million for the nine months ended October 1, 2021. ICL sales represented 93.2% and 86.5% of our total sales for the nine months ended October 1, 2021 and October 2, 2020, respectively.

Other product sales, including cataract IOLs were $4.2 million for the three months ended October 1, 2021, a decrease of 25% from $5.6 million reported for the same period of 2020, due to decreased sales of cataract IOLs and low margin injector part sales. Other product sales were $11.6 million for the nine months ended October 1, 2021, a decrease of 27% from $15.9 million reported for the same period of 2020, mainly due to product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers, as well as decreased cataract IOL sales. Changes in foreign currency unfavorably impacted other product sales by $0.1 million for the three October 1, 2021 and favorably impacted other product sales by $0.1 million for the nine months ended October 1, 2021. Other product sales represented 7.2% and 11.9% of our total sales for the three months ended October 1, 2021 and October 2, 2020, respectively, and represented 6.8% and 13.5% of our total sales for the nine months ended October 1, 2021 and October 2, 2020, respectively.

Gross Profit

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
Gross profit |  | $ | 45,301 |  |  | $ | 34,871 |  |  |  | 29.9 | % |  | $ | 133,646 |  |  | $ | 84,061 |  |  |  | 59.0 | %
Gross margin |  |  | 77.6 | % |  |  | 74.1 | % |  |  |  |  |  |  | 77.9 | % |  |  | 71.6 | % |  |  |  |

* | Denotes change is greater than +100%.

Gross profit for the three months ended October 1, 2021 was $45.3 million, a 29.9% increase compared to the $34.9 million reported for the same period of 2020. Gross profit margin increased to 77.6% of revenue for the three months ended October 1, 2021 compared to 74.1% of revenue for the three months ended October 2, 2020, due to geographic sales mix and a decreased mix of injector part sales which carry a lower margin, partially offset by increased period costs associated with manufacturing projects for the three months ended October 1, 2021.

Gross profit for the nine months ended October 1, 2021 was $133.6 million, a 59.0% increase compared to the $84.1 million reported for the same period of 2020. Gross profit margin increased to 77.9% of revenue for the nine months ended October 1, 2021 compared to 71.6% of revenue for the nine months ended October 2, 2020, due to geographic sales mix, a decreased mix of injector part sales which carry a lower margin, and for the nine months ended October 2, 2020 there were $1.2 million period costs recorded as a result of COVID-19 and the resulting manufacturing pause from March 17, 2020 through April 27, 2020, partially offset by increased period costs associated with manufacturing projects for the nine months ended October 1, 2021.

20

General and Administrative Expense

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
General and administrative expense |  | $ | 11,018 |  |  | $ | 8,589 |  |  |  | 28.3 | % |  | $ | 32,671 |  |  | $ | 24,406 |  |  |  | 33.9 | %
Percentage of sales |  |  | 18.9 | % |  |  | 18.2 | % |  |  |  |  |  |  | 19.0 | % |  |  | 20.8 | % |  |  |  |

General and administrative expenses for the three months ended October 1, 2021 were $11.0 million, a 28.3% increase compared to the $8.6 million reported for the same period of 2020 due to due to increased bonus and stock-based compensation expenses, salary-related and payroll tax expenses and outside services. General and administrative expenses for the nine months ended October 1, 2021 were $32.7 million, a 33.9% increase compared to the $24.4 million reported for the same period of 2020 due to increased bonus and stock-based compensation expenses, salary-related and payroll tax expenses, outside services, corporate insurance and facilities costs.

Selling and Marketing Expense

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
Selling and marketing expense |  | $ | 18,175 |  |  | $ | 12,649 |  |  |  | 43.7 | % |  | $ | 50,229 |  |  | $ | 34,003 |  |  |  | 47.7 | %
Percentage of sales |  |  | 31.1 | % |  |  | 26.9 | % |  |  |  |  |  |  | 29.3 | % |  |  | 29.0 | % |  |  |  |

Selling and marketing expenses for the three months ended October 1, 2021 were $18.2 million, a 43.7% increase compared to the $12.6 million reported for the same period of 2020 due to increased advertising and promotional activities, salary-related and payroll tax expenses and trade shows expenses. Selling and marketing expenses for the nine months ended October 1, 2021 were $50.2 million, a 47.7% increase compared to the $34.0 million reported for the same period of 2020 due to advertising and promotional activities, salary-related and payroll tax expenses, commission expense, trade shows expense and bonus expenses.

Research and Development Expense

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
Research and development expense |  | $ | 8,271 |  |  | $ | 8,751 |  |  |  | (5.5 | )% |  | $ | 24,790 |  |  | $ | 22,960 |  |  |  | 8.0 | %
Percentage of sales |  |  | 14.2 | % |  |  | 18.6 | % |  |  |  |  |  |  | 14.5 | % |  |  | 19.5 | % |  |  |  |

Research and development expenses for the three months ended October 1, 2021 were $8.3 million, a 5.5% decrease compared to the $8.8 million reported for the same period of 2020 due mainly to decreased clinical expenses associated with our EVO clinical trial. Research and development expenses for the nine months ended October 1, 2021 were $24.8 million, an 8.0% increase compared to the $23.0 million reported for the same period of 2020 due to increased bonus and stock-based compensation expenses and salary-related and payroll tax expenses, partially offset by decreased clinical expenses associated with our EVO clinical trial.

Other Income (Expense), Net

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
Other income (expense), net |  | $ | (461 | ) |  | $ | 499 |  |  |  | —* |  |  | $ | (1,626 | ) |  | $ | 781 |  |  |  | —* |
Percentage of sales |  |  | (0.8 | )% |  |  | 1.1 | % |  |  |  |  |  |  | (0.9 | )% |  |  | 0.7 | % |  |  |  |

* | Denotes change is greater than +100%.

21

Other expense, net for the three and nine months ended October 1, 2021 was $0.5 million and $1.6 million, respectively, compared to other income, net of $0.5 million and $0.8 million, respectively, reported for the same period of 2020 due primarily to increased foreign exchange losses (primarily euro).

Income Taxes

|  | Three Months Ended |  |  | Percentage Change |  |  | Nine Months Ended |  |  | Percentage Change |
|  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |  |  | October 1, 2021 |  |  | October 2, 2020 |  |  | 2021 vs. 2020 |
Income tax provision |  | $ | 1,356 |  |  | $ | 1,489 |  |  |  | (8.9 | )% |  | $ | 4,751 |  |  | $ | 887 |  |  |  | —* |

* | Denotes change is greater than +100%.

We recorded income taxes of $1.4 million and $4.8 million for the three and nine months ended October 1, 2021, respectively, due to pre-tax income generated in certain foreign jurisdictions and, for the nine months ended October 1 2021, a recapture of our U.S. valuation allowance of $0.8 million as a result of increased tax deductions in the projection of taxable income used in our valuation assessment. The Company, from time to time may adjust the projections of taxable income as a result of current conditions. We recorded income taxes of $1.5 million for the three months ended October 2, 2020 due to pre-tax income generated in certain foreign jurisdictions, partially offset by a reversal of $0.2 million of its U.S. valuation allowance, as a result of an increase in foreign income and changes in the usage and release of certain deferred tax assets. We recorded an income taxes of $0.9 million for the nine months ended October 2, 2020 due to pre-tax income generated in certain foreign jurisdictions, offset by a release of our U.S. valuation allowance of $1.2 million, as a result of us revising our global forecasts in response to the impacts of COVID-19, and due to changes in the usage and release of certain deferred tax assets.

ASC 740 requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred tax asset may not be realizable. The ultimate realization of deferred tax assets is dependent upon future generation of income during the periods in which temporary differences representing net future deductible amounts become deductible. In evaluating our ability to recover our deferred tax assets, we consider among other things, projected future income, tax planning strategies and all other available evidence both positive and negative in making this assessment. The “incremental cash tax savings approach” is further described in Notes 1 and 10 of the Company’s fiscal 2020 Form 10-K. Under the incremental cash tax savings approach, our cumulative valuation allowance recorded was $38.4 million and $8.1 million for federal and state, respectively, at October 1, 2021, and $34.7 million and $7.4 million for federal and state, respectively, at January 1, 2021. Under the incremental cash tax savings approach, the valuation allowance recorded reflects the net operating losses and deferred tax assets which will not result in future cash tax savings and therefore provide no additional benefit. Total U.S. net deferred tax assets were $3.0 million and $3.9 million as of October 1, 2021 and January 1, 2021, respectively.

Liquidity and Capital Resources

We believe that current cash, cash equivalents and future cash flow from operating activities will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements included in this quarterly report. Although we have experienced some delays in payments on accounts receivable as a result of the COVID-19 pandemic in the first half of 2020, this has improved since the third quarter of 2020 as our customers resume elective refractive surgery. We are unaware of any impairment of assets resulting from the COVID-19 pandemic. The Company did not apply for or require financing available under the Coronavirus Aid, Relief, and Economic Security “CARES” Act and does not expect to do so given the strength of our balance sheet. Our financial condition at October 1, 2021 and January 1, 2021 included the following (in millions):

|  | October 1, 2021 |  |  | January 1, 2021 |  |  | 2021 vs. 2020 |
Cash and cash equivalents |  | $ | 196.2 |  |  | $ | 152.5 |  |  | $ | 43.7 |
Current assets |  | $ | 263.9 |  |  | $ | 216.4 |  |  | $ | 47.5 |
Current liabilities |  |  | 46.8 |  |  |  | 41.2 |  |  |  | 5.6 |
Working capital |  | $ | 217.1 |  |  | $ | 175.2 |  |  | $ | 41.9 |

We invest the net proceeds in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. Additionally, at October 1, 2021, we have a line of credit

22

with a Japane se lender, in the amount of $1.3 million, with $3.2 million of availability. We expect to repay this credit facility in full upon maturity at November 21, 2021.

Net cash provided by operating activities was $35.5 million for the nine months ended October 1, 2021 compared to $1.4 million for the nine months ended October 2, 2020. Net cash provided by operating activities for the nine months ended October 1, 2021, consisted of $19.6 million in net income, $16.8 in non-cash items, offset by $0.9 million in working-capital changes. The increase in net cash provided by operating activities during the nine months ended October 1, 2021 was due to changes in net income of $17.0 million, net working capital of $12.9 million and non-cash items of $4.2 million.

Net cash used in investing activities was $9.0 million and $6.3 million for the nine months ended October 1, 2021 and October 2, 2020, respectively, and relate primarily to the acquisition of property, plant, and equipment, due to increased investments in manufacturing and leasehold improvements intending to satisfy growing demand for our products.

Net cash provided by financing activities was $18.0 million and $13.0 million for the nine months ended October 1, 2021 and October 2, 2020, respectively. Net cash provided by financing activities for the nine months ended October 1, 2021 consisted of $18.3 million of proceeds from the exercise of stock options, partially offset by $0.3 million repayment of finance lease obligations.

Credit Facilities and Commitments

Lines of Credit and Leases

See Notes 7 and 8 of the accompanying Condensed Consolidated Financial Statements.

Covenant Compliance

The Company is in compliance with the covenants of its credit facility as of October 1, 2021.

Employment Agreements

The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective March 1, 2015. She and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as that term is defined in the rules of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

During the nine months ended October 1, 2021, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended January 1, 2021.

ITEM 4. | CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s

23

management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended October 1, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. | LEGAL PROCEEDINGS

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business. These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability. STAAR maintains insurance coverage for various matters, including product liability and certain securities claims. While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.

ITEM 1A. | RISK FACTORS

Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended January 1, 2021. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.

ITEM 4. | MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. | OTHER INFORMATION

None.

24

ITEM 6. | EXHIBITS

3.1 | Amended and Restated Certificate of Incorporation.(1)
3.2 | Amended and Restated Bylaws.(2)
4.1 | Form of Certificate for Common Stock, par value $0.01 per share.(3)
†4.2 | Amended and Restated Omnibus Equity Incentive Plan.(4)
31.1 | Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2 | Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1 | Certification Pursuant to 18 U.S.C. Section 1350, Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **
101 | Financial statements from the quarterly report on Form 10-Q of STAAR Surgical Company for the quarter ended October 1, 2021 formatted in Inline Extensible Business Reporting Language (iXBRL), are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.*
104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended October 1, 2021, has been formatted in Inline XBRL with applicable taxonomy extension information contained in Exhibit 101.

(1) | Incorporated by reference to Appendix 2 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018.

(2) | Incorporated by reference to Appendix 3 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 13, 2018.

(3) | Incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form 8‑A/A as filed with the Commission on April 18, 2003.

(4) | Incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q, for the period ended July 3, 2020, as filed with the Commission on August 5, 2020.

* | Filed herewith.

** | Furnished herewith.

† | Management contract or compensatory plan.

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  | STAAR SURGICAL COMPANY
Dated: |  | November 3, 2021 | By: |  | /s/ PATRICK F. WILLIAMS
|  |  |  |  | Patrick F. Williams
|  |  |  |  | Chief Financial Officer
|  |  |  |  | (on behalf of the Registrant and as its principal financial officer)

26